Transgene S.A. is a biotechnology company specializing in the research and development of targeted immunotherapies for cancer. The company designs innovative therapeutic vaccines and oncolytic virus products intended to activate and harness the patient’s immune system against various malignancies. Leveraging advanced genetic engineering and artificial intelligence, Transgene’s portfolio includes individualized neoantigen cancer vaccines, such as those developed with its myvac® platform, tailored to match the unique tumor characteristics of each patient. Additionally, Transgene’s invir.IO® platform focuses on multifunctional oncolytic viruses engineered to modulate the tumor microenvironment, enhancing the body’s natural ability to identify and attack cancer cells. The company's approach integrates multidisciplinary collaboration and technology to advance next-generation cancer treatments, positioning it at the forefront of immunotherapy innovation in the healthcare and biotechnology sectors.